[1] Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018. doi:10.1016/S0140-6736(17)33326-3.
[2] Rossi S, Baili P, Capocaccia R, Caldora M, Carrani E, Minicozzi P, et al. The EUROCARE-5 study on cancer survival in Europe 1999-2007: Database, quality checks and statistical analysis methods. Eur J Cancer 2015. doi:10.1016/j.ejca.2015.08.001.
[3] A.M. Noone et al. SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER web site, April 2018.
[4] Horowitz NS, Miller A, Rungruang B, Richard SD, Rodriguez N, Bookman MA, et al. Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: An analysis of GOG 182. J Clin Oncol 2015. doi:10.1200/JCO.2014.56.3106.
[5] National Comprehensive Cancer Network. Ovarian Cancer Incuding Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 4.2017
https://www2.trikobe.org/nccn/guideline/gynecological/english/ovarian.pdf. Accessed 1 May 2019.
[6] Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins WJ, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996. doi:10.1200/JCO.1996.14.5.1545.
[7] http://labogids.sintmaria.be/sites/default/files/files/ca_125_ii_2017-05_v1.pdf [accessed 1 May 2019]
[8] van Belle, L.D. Fisher, P.J. Heagerty i T. Lumley. Biostatistics. A Methodology for the
Health Sciences. John Wiley & Sons, Inc., Hoboken, New Jersey, USA, 2004.
[9] Davidson NGP, Khanna S, Kirwan PH, Bircumshaw D. Prechemotherapy serum CA125 level as a predictor of survival outcome in epithelial carcinoma of the ovary. Clin Oncol 1991. doi:10.1016/S0936-6555(05)81038-6.
[10] Gronlund B, Dehn H, Høgdall CK, Engelholm SA, Jørgensen M, Nørgaard-Pedersen B, et al. Cancer-associated serum antigen level: A novel prognostic indicator for survival in patients with recurrent ovarian carcinoma. Int J Gynecol Cancer 2005. doi:10.1111/j.1525-1438.2005.00145.x.
[11] Makar APH, Kristensen GB, Kaern J, Bormer OP, Abeler VM, Trope CG. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: New aspects and multivariate analysis. Int J Gynecol Obstet 2004. doi:10.1016/0020-7292(93)90406-m.
[12] Badulescu F, Badulescu A, Schenker M, Popescu CF, Stoica Z. The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma. Rom J Morphol Embryol 2005.
[13] Kim HS, Park NH, Chung HH, Kim JW, Song YS, Kang SB. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders’ survival in patients with advanced epithelial ovarian cancer. Onkologie 2008. doi:10.1159/000131270.
[14] Petri AL, Høgdall E, Christensen IJ, Kjaer SK, Blaakær J, Høgdall CK. Preoperative CA125 as a prognostic factor in stage I epithelial ovarian cancer. APMIS 2006. doi:10.1111/j.1600-0463.2006.apm_397.x.
[15] Čolaković S, Lukiç V, Mitroviç L, Jeliç S, Šušnjar S, Marinkoviç J. Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer. Int J Biol Markers 2000.
[16] Wilder JL, Pavlik E, Straughn JM, Kirby T, Higgins R V., DePriest PD, et al. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: A preliminary investigation. Gynecol. Oncol., 2003. doi:10.1016/S0090-8258(03)00051-9.
[17] Santillan A, Garg R, Zahurak ML, Gardner GJ, Giuntoli RL, Armstrong DK, et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol 2005. doi:10.1200/JCO.2005.02.2582.
[18] Wang F, Ye Y, Xu X, Zhou X, Wang J, Chen X. CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery. J Ovarian Res 2013. doi:10.1186/1757-2215-6-14.
[19] Liu PY, Alberts DS, Monk BJ, Brady M, Moon J, Markman M. An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol 2007. doi:10.1200/JCO.2006.09.4540.
[20] Levy T, Weiser R, Boaz M, Shem E Ben, Golan A, Menczer J. Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian, primary peritoneal, and tubal cancers, who, after initial treatment, had a complete clinical response. Int J Gynecol Cancer 2012. doi:10.1097/IGC.0b013e3182691254.
[21] Azad NS, Annunziata CM, Steinberg SM, Minasian L, Premkumar A, Chow C, et al Lack of reliability of CA125 response criteria with anti‐VEGF molecularly targeted therapy. Cancer 2008; 15;112(8):1726-32. doi: 10.1002/cncr.23374